Literature DB >> 21317706

S100P expression in ductal type of carcinoma ex pleomorphic adenoma.

Kazuki Hashimoto1, Hidetaka Yamamoto, Hideki Shiratsuchi, Torahiko Nakashima, Sadafumi Tamiya, Yuichiro Higaki, Shizuo Komune, Masazumi Tsuneyoshi, Yoshinao Oda.   

Abstract

Pleomorphic adenoma (PA) is known to occasionally progress to carcinoma, but the mechanisms of its malignant transformation have not been fully elucidated. S100P, an EF-hand calcium-binding protein, has recently been proposed as an initiator of carcinogenesis in some kinds of epithelial tumors. In this study, we aimed to elucidate the potential role of S100P in tumorigenesis and stepwise progression of carcinoma ex pleomorphic adenoma (CXPA) with ductal differentiation. In 31 ductal type CXPAs (8 in situ, 5 intracapsular, and 18 extracapsular) and 28 PAs (21 conventional and 7 atypical) of the salivary gland, we examined the protein expression of S100P, androgen receptor (AR), HER2/neu, p53, and Ki-67 by immunohistochemistry. HER2 expression, p53 expression, and the Ki-67 labeling index were higher in CXPAs than in atypical PAs and conventional PAs, whereas the AR expression level was relatively high even in atypical PAs. S100P overexpression was significantly more prevalent in CXPAs (27 cases; 87.1%) than in atypical PAs (2 cases; 28.6%) and conventional PAs (1 case; 4.8%) (P<0.05). High prevalence of S100P expression was observed in each intraductal, extraductal-intracapsular, and extracapsular component of CXPAs. In addition, equivalent, high-level S100P expression was observed in all histologic subtypes of the malignant component of CXPAs. These results indicate that S100P may play an important role in malignant transformation of ductal cells of PA, and that immunohistochemical staining for S100P would be a useful diagnostic marker for identifying the early phase of CXPA, in combination with AR, HER2, p53, and Ki-67.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317706     DOI: 10.1097/PAS.0b013e31820832a6

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Immunohistochemical expression of p16 in Carcinoma Ex-pleomorphic Adenoma (undifferentiated and Adenocarcinoma Types).

Authors:  Bassel Tarakji; Mohammed Alsakran Altamimi; Kusai Baroudi; Mohammad Z Nassain; Faris Q Alenzi
Journal:  J Clin Diagn Res       Date:  2013-12-15

2.  Carcinosarcoma ex non-recurrent pleomorphic adenoma composed of TTF-1 positive large cell neuroendocrine carcinoma and myofibrosarcoma: apropos a rare Case.

Authors:  Fredrik Petersson; Kwok Seng Loh
Journal:  Head Neck Pathol       Date:  2012-07-31

Review 3.  Clinicopathologic and immunohistochemical features of primary ductal adenocarcinoma of lacrimal gland: five new cases and review of literature.

Authors:  Toshinobu Kubota; Suzuko Moritani; Shu Ichihara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-24       Impact factor: 3.117

4.  Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.

Authors:  Jeong Won Kim; Gui Young Kwon; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim; Kyung-Ja Cho
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

5.  The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan.

Authors:  Kimihide Kusafuka; Yoko Sato; Eiji Nakatani; Satoshi Baba; Matsuyoshi Maeda; Koji Yamanegi; Kaori Ueda; Hiroshi Inagaki; Yoshiro Otsuki; Naoto Kuroda; Kensuke Suzuki; Hiroshi Iwai; Yoshiaki Imamura; Junya Itakura; Shoji Yamanaka; Hideaki Takahashi; Ichiro Ito; Takumi Akashi; Tsutomu Daa; Mei Hamada; Masanori Yasuda; Ryo Kawata; Hidetaka Yamamoto; Yuri Tachibana; Junya Fukuoka; Aya Muramatsu; Kazumori Arai; Makoto Suzuki
Journal:  Head Neck       Date:  2022-03-29       Impact factor: 3.821

6.  Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice.

Authors:  Toshitaka Nagao; Eiichi Sato; Rie Inoue; Hisashi Oshiro; Reisuke H Takahashi; Takeshi Nagai; Maki Yoshida; Fumie Suzuki; Hiyo Obikane; Mitsumasa Yamashina; Jun Matsubayashi
Journal:  Acta Histochem Cytochem       Date:  2012-09-22       Impact factor: 1.938

7.  Basal cell adenocarcinoma of the salivary gland: a morphological and immunohistochemical comparison with basal cell adenoma with and without capsular invasion.

Authors:  Min Jung Jung; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim; Sang-Wook Lee; Kyung-Ja Cho
Journal:  Diagn Pathol       Date:  2013-10-21       Impact factor: 2.644

8.  Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.

Authors:  Shigenori Kadowaki; Yasushi Yatabe; Hitoshi Hirakawa; Azusa Komori; Chihiro Kondoh; Yasuhisa Hasegawa; Kei Muro
Journal:  Case Rep Oncol       Date:  2013-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.